ArticleEuropean radiology2025
Dual-energy CT for differentiation of hypodense liver lesions in pancreatic adenocarcinoma.
Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Practical applications of photon-counting CT in oncology: an organ-based pictorial review.Insights into imaging · 2026Article
- Conspicuity and characterization of pre-selected hypodense hepatic lesions in pancreatic cancer patients: limited clinical value of dual-energy portal phase CT.Abdominal radiology (New York) · 2026Article
- Precision imaging biomarkers for gout: artifact-specific spectral CT parameters for personalized differentiation of tophi in a prospective study.Therapeutic advances in musculoskeletal disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo assess the accuracy of CT spectral HU curve assessment of hypodense liver lesions.
methodsIn this retrospective HIPAA-compliant study (January 2016 through May 2023), patients with biopsy-proven pancreatic adenocarcinoma and a biopsied indeterminate liver lesion underwent a DECT abdominal CT scan. Spectral HU curves were provided for each hypodense liver lesion, and slopes were calculated. Lesion Hounsfield units, iodine concentration and virtual enhancement were recorded. The Wilcoxon rank sum test was used to compare malignant and benign lesions. Optimal cutoff points were estimated using ROC curves and Youden's Index.
resultsThirty-six patients (19 men, 17 women) with a mean age of 63 years ± 9 (standard deviation), a mean height of 170.9 cm ± 9.5, a mean weight of 69.8 kg ± 14.5, and a body mass index of 23.9 kg/m
conclusionSpectral HU curves and iodine concentration of well-defined hypodense liver lesions are highly accurate in the diagnosis of benign versus malignant lesions. KEY POINTS: Question Limited evidence exists for spectral imaging diagnosis of liver lesions-can DECT accurately differentiate between benign and metastatic hypodense liver lesions? Findings Ninety-two hypodense liver lesions evaluated using HU keV curve slope, iodine concentration, and virtual enhancement resulted in accurate benign versus metastatic differentiation. Clinical relevance Hypodense liver lesions are a challenging issue at staging, often requiring further imaging, follow-up, and/or biopsy. The additional information from multi-energy CT can be useful to differentiate between benign and malignant lesions, thereby reducing the need for costly additional evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.